SANTERO THERAPEUTICS DEVELOPS FIRST-IN-CLASS ANTIMICROBIALS WITH NEW MODE OF ACTION, TO ADDRESS THE EMERGENCE OF ANTIBIOTIC RESISTANT BACTERIA
Santero Therapeutics SRL is a spin-off biotech from the Université Libre de Bruxelles founded in 2021 by Professors Cédric Govaerts, PhD and Abel Garcia-Pino, PhD The company is anchored in more than a decade of fundamental research carried out in the labs of the Founders. Santero Therapeutics aims to deliver innovative drugs with new mode of actions that target highly resistant pathogens.
IS A LEADING SCIENTIST IN THE STUDY OF BACTERIAL SURVIVAL TO STRESS, ANTIBIOTIC RESISTANCE, AND DEVELOPMENT OF NEW THERAPEUTICS AGAINST BACTERIAL INFECTIONS. HIS RESEARCH HAS BEEN SUPPORTED BY DIFFERENT FUNDING BODIES IN BELGIUM AND ABROAD AND WAS AWARDED AN ERC GRANT
IS A LEADING SCIENTIST IN THE FIELD OF ANTIBIOTIC EXTRUSION AND DEVELOPMENT OF NEW THERAPEUTIC AGAINST CYSTIC FIBROSIS. HIS WORK WAS SUPPORTED BY BELGIAN FUNDING BODIES AND NUMEROUS FOUNDATIONS.
« Antibiotic resistance makes once treatable infections untreatable, unlike COVID-19 there will never be herd immunity to antibiotic resistant infections, nor a universal vaccine, the impact of antibiotic resistance will dwarf the impact of COVID-19 over the next decade. »